The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Inclusion Criteria:

Male or non-pregnant female > 18 years of age;
Documentation of heart failure and who are in NYHA class II or III;
Documented history of symptomatic AF < 6 months in duration at the time of presentation, currently in AF at the time of the external electrical cardioversion, and successfully restored to normal sinus rhythm;
Percutaneous coronary intervention (PCI) patients who can be placed on anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or dabigatran);
Demonstration of preserved ejection fraction (EF) by echocardiography;
Echocardiographic evidence of impaired diastolic filling.

Exclusion Criteria:

Known history of permanent or long-standing AF (> 6 months);
Other acutely reversible causes of AF, including but not limited to: hyperthyroidism, pericarditis, myocarditis or pulmonary embolism;
Known history of cirrhosis;
NYHA Class IV;
Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery within three months prior to screening;
Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these patients need to be placed on rivaroxaban or dabigatran post-cardioversion;
Clinically significant valvular disease;
Clinically significant pulmonary disease;
Stroke within 3 months prior to screening;
Creatinine clearance < 30 mL/min as calculated by Cockcroft-Gault formula;
Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;
Concurrent use of drugs considered strong inhibitors of CYP3A;
Concurrent use of drugs considered as CYP3A inducers;
Prior treatment with ranolazine.